GPRC5A and cancer: Moreover, since hypoxia frequently occurs in the therapy‐resistant regions of tumours where the utility of hypoxia‐targeted drugs is limited, the development of inhibitors to GPRC5A may lead to novel cancer‐selective drugs that could serve as adjuncts to conventional chemo‐ and radiotherapy.